Designed for cataract patients, the TECNIS Odyssey aims to reduce the need for glasses by offering a full range of precise vision at all distances.
Johnson & Johnson (J&J) announced an expanded rollout in the United States for the TECNIS Odyssey, a presbyopia-correcting intraocular lens (PC-IOL). According to the company, the TECNIS Odyssey offers patients a full range of precise vision from far to near and in between, minimizing their need for glasses. J&J added that ECNIS Odyssey delivers two times better contrast in low light than PanOptix.1
“More than 14,000 eyes have already benefited from TECNIS Odyssey, our new full visual range IOL. TECNIS Odyssey patients have reported outstanding visual outcomes following surgery, which is why we are excited to announce we are expanding the roll-out across the US today,” said Peter Menziuso, group chairman, vision, Johnson & Johnson, in a press release. “Cataract surgery gives patients a once in a lifetime opportunity to improve their sight, and now with this advanced IOL, patients can see clearly at every distance, without the need for glasses.”
J&J first offered a preview of the TECNIS Odyssey’s functions at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting in April 2024.2 Clinical results in early trials have found that 94% of patients were satisfied with their vision without glasses, 92% reported clear night vision, 97% were satisfied with distance vision, and 96% were satisfied with reading a smartphone or tablet.
J&J warns that intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition, or may pose an unreasonable risk to the eyesight of patients. Physicians should weigh the potential risks and benefits for each patient with caution. Additionally, patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not experience the full benefits of the TECNIS Odyssey.
Approximately 20.5 million people in the United States over 40 years of age are currently living with a cataract in one or both of their eyes. However, only 6.1 million have had surgery to correct the issue. People with cataracts also commonly experience other problems with their vision, such as presbyopia.1
According to News Medical Life Sciences, changes in the health of the eye lens due to aging have been reported by 42% of those aged 52 to 64 years, 60% in people aged 65 to 74 years, and 91% in people aged 75 to 85 years. In developing countries such as India, 82% of people between the ages of 75 and 83 years are affected by cataracts, while in the United States, only 46% in the same age group have them. It is believed that as the aging population increases globally, the number of people with cataracts will increase as well.3
“The TECNIS Odyssey IOL is perhaps the most comprehensive and well-balanced PC-IOL on the market to date,” said George O. Waring IV, medical director, Waring Vision Institute, Mt. Pleasant, SC, in the press release. “It falls under a new standard of full vision range that provides extraordinary contrast in both day and night-time conditions, tolerance to refractive error and minimal dysphotopsias with outstanding contrast sensitivity that really takes it to a whole different level and nothing like we’ve seen before with prior PC-IOLs.”
J&J also plans to launch the TECNIS Odyssey IOL Peer Connect, an initiative to support clinical dialogue between surgeons and eye care professionals. The TECNIS Odyssey IOL has also received regulatory approval in Japan, EU, Korea, Canada, Singapore, Australia and New Zealand.1
References
1. Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting. J&J. September 30, 2024. Accessed September 30, 2024. https://www.jnj.com/media-center/press-releases/johnson-johnson-rolls-out-new-tecnis-odyssey-next-generation-intraocular-lens-offering-cataract-patients-precise-vision-at-every-distance-in-any-lighting
2. Johnson & Johnson Debuts NEW Full Visual Range Presbyopia Correcting IOL TECNIS Odyssey at the 2024 ASCRS Annual Meeting. J&J. March 28, 2024. Accessed September 30, 2024. https://www.jjvision.com/press-release/johnson-johnson-debuts-new-full-visual-range-presbyopia-correcting-iol-tecnis-odyssey
3. Cataract Epidemiology. News Medical Life Sciences. Accessed September 30, 2024. https://www.news-medical.net/health/Cataract-Epidemiology.aspx
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.